PE20181301A1 - Bloqueador del canal de sodio - Google Patents
Bloqueador del canal de sodioInfo
- Publication number
- PE20181301A1 PE20181301A1 PE2018000765A PE2018000765A PE20181301A1 PE 20181301 A1 PE20181301 A1 PE 20181301A1 PE 2018000765 A PE2018000765 A PE 2018000765A PE 2018000765 A PE2018000765 A PE 2018000765A PE 20181301 A1 PE20181301 A1 PE 20181301A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrogen
- alkyl
- alkylene
- sodium channel
- halogen
- Prior art date
Links
- 239000003195 sodium channel blocking agent Substances 0.000 title abstract 2
- 229940125794 sodium channel blocker Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 229910052736 halogen Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 208000006820 Arthralgia Diseases 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referido a un compuesto de Formula (I), en donde R1 es hidrogeno, alquilo C1-4, alcoxilo C1-4, entre otros; R2 y R3 son cada uno independientemente hidrogeno o halogeno; R4 es heteroarilo C5-10, que contiene uno o dos elementos cada uno seleccionado independientemente del grupo que consiste en N, S y O; R5 es -CH2CH2-N(R7)(R8) o -CH2CH2CH2-N(R7)(R8); R6 es hidrogeno o alquilo C1-4; R5 y R6 forman juntos alquileno C3-5, (alquileno C2-4)-N(R9)-(alquileno C2-4), entre otros; R7, R8 y R9 son cada uno independientemente hidrogeno o alquilo C1-4; X1 es C-R´o N, en el que R´ es hidrogeno o halogeno; X2 es CH o N y X3 es N-R´´, en el que R´´ es hidrogeno o alquilo C1-4. Estos compuestos tienen actividad bloqueante de canales de ion sodio. Tambien se refiere a una composicion farmaceutica que contiene dicho compuesto, la cual se utiliza en la prevencion o tratamiento de enfermedades relacionadas con bloqueantes de canales de sodio como, dolor agudo, dolor cronico, migrana, dolor neuropatico, artralgia, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150159637 | 2015-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181301A1 true PE20181301A1 (es) | 2018-08-09 |
Family
ID=58695815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000765A PE20181301A1 (es) | 2015-11-13 | 2016-11-11 | Bloqueador del canal de sodio |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10227338B2 (es) |
| EP (1) | EP3375782B1 (es) |
| JP (1) | JP6559894B2 (es) |
| KR (1) | KR102245930B1 (es) |
| CN (1) | CN108349963B (es) |
| AU (1) | AU2016351526B2 (es) |
| BR (1) | BR112018009754B1 (es) |
| CA (1) | CA3003119C (es) |
| CL (1) | CL2018001281A1 (es) |
| CO (1) | CO2018005064A2 (es) |
| EC (1) | ECSP18038014A (es) |
| ES (1) | ES2821962T3 (es) |
| HR (1) | HRP20201695T1 (es) |
| HU (1) | HUE052569T2 (es) |
| MA (1) | MA43231B1 (es) |
| MX (1) | MX376469B (es) |
| MY (1) | MY194015A (es) |
| NZ (1) | NZ742069A (es) |
| PE (1) | PE20181301A1 (es) |
| PH (1) | PH12018500999A1 (es) |
| PL (1) | PL3375782T3 (es) |
| PT (1) | PT3375782T (es) |
| RS (1) | RS60927B1 (es) |
| RU (1) | RU2705578C1 (es) |
| SA (1) | SA518391540B1 (es) |
| SG (1) | SG11201803867TA (es) |
| SI (1) | SI3375782T1 (es) |
| TN (1) | TN2018000157A1 (es) |
| WO (1) | WO2017082688A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110072855A (zh) * | 2016-10-17 | 2019-07-30 | 基因泰克公司 | 治疗性化合物及其使用方法 |
| TW202003490A (zh) * | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2020052509A1 (zh) * | 2018-09-10 | 2020-03-19 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
| CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| KR100886854B1 (ko) * | 2001-03-12 | 2009-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | Ｎ-페닐아릴설폰아미드 화합물, 이 화합물을 유효성분으로서 함유하는 약제, 이 화합물의 합성 중간체 및이의 제조 방법 |
| JP2006290791A (ja) | 2005-04-11 | 2006-10-26 | Astellas Pharma Inc | アゾール置換スルホニルベンゼン誘導体 |
| US20090221581A1 (en) * | 2005-05-25 | 2009-09-03 | Philipp Wabnitz | Methods of treating pain |
| US7888345B2 (en) | 2006-06-09 | 2011-02-15 | Merck Sharp & Dohme Corp. | Benzaepinones as sodium channel blockers |
| EP2139852A1 (en) * | 2006-12-19 | 2010-01-06 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| JP2008290791A (ja) * | 2007-05-22 | 2008-12-04 | Funai Electric Co Ltd | 画像形成装置 |
| US8124610B2 (en) * | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| CU24099B1 (es) * | 2009-01-12 | 2015-06-30 | Pfizer Ltd | Derivados de sulfonamida para el tratamiento del dolor |
| EP2593432B1 (en) * | 2010-07-12 | 2014-10-22 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
| CN104093716B (zh) * | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US9085517B2 (en) | 2011-12-15 | 2015-07-21 | Pfizer Limited | Sulfonamide derivatives |
| WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
| AR091112A1 (es) | 2012-05-22 | 2015-01-14 | Genentech Inc | Benzamidas n-sustituidas como inhibidores de los canales de sodio nav1.7 |
| EP3444249B1 (en) * | 2012-10-15 | 2020-05-13 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| WO2015130957A1 (en) * | 2014-02-27 | 2015-09-03 | Zalicus Pharmaceuticals, Ltd. | Heterocyclic inhibitors of the sodium channel |
-
2016
- 2016-11-11 KR KR1020160150511A patent/KR102245930B1/ko active Active
- 2016-11-11 WO PCT/KR2016/013029 patent/WO2017082688A1/ko not_active Ceased
- 2016-11-11 HU HUE16864614A patent/HUE052569T2/hu unknown
- 2016-11-11 SG SG11201803867TA patent/SG11201803867TA/en unknown
- 2016-11-11 AU AU2016351526A patent/AU2016351526B2/en active Active
- 2016-11-11 CA CA3003119A patent/CA3003119C/en active Active
- 2016-11-11 MX MX2018005940A patent/MX376469B/es active IP Right Grant
- 2016-11-11 RS RS20201235A patent/RS60927B1/sr unknown
- 2016-11-11 JP JP2018524451A patent/JP6559894B2/ja active Active
- 2016-11-11 MA MA43231A patent/MA43231B1/fr unknown
- 2016-11-11 EP EP16864614.9A patent/EP3375782B1/en active Active
- 2016-11-11 PL PL16864614.9T patent/PL3375782T3/pl unknown
- 2016-11-11 BR BR112018009754-3A patent/BR112018009754B1/pt active IP Right Grant
- 2016-11-11 TN TNP/2018/000157A patent/TN2018000157A1/en unknown
- 2016-11-11 PE PE2018000765A patent/PE20181301A1/es unknown
- 2016-11-11 HR HRP20201695TT patent/HRP20201695T1/hr unknown
- 2016-11-11 ES ES16864614T patent/ES2821962T3/es active Active
- 2016-11-11 RU RU2018119954A patent/RU2705578C1/ru active
- 2016-11-11 MY MYPI2018000662A patent/MY194015A/en unknown
- 2016-11-11 US US15/771,775 patent/US10227338B2/en active Active
- 2016-11-11 CN CN201680066269.7A patent/CN108349963B/zh active Active
- 2016-11-11 SI SI201630902T patent/SI3375782T1/sl unknown
- 2016-11-11 NZ NZ742069A patent/NZ742069A/en unknown
- 2016-11-11 PT PT168646149T patent/PT3375782T/pt unknown
-
2018
- 2018-05-08 PH PH12018500999A patent/PH12018500999A1/en unknown
- 2018-05-09 SA SA518391540A patent/SA518391540B1/ar unknown
- 2018-05-10 CL CL2018001281A patent/CL2018001281A1/es unknown
- 2018-05-11 CO CONC2018/0005064A patent/CO2018005064A2/es unknown
- 2018-05-18 EC ECIEPI201838014A patent/ECSP18038014A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221339A1 (es) | Inhibidores de parp1 | |
| EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
| EA202091484A1 (ru) | 4-азаиндольные соединения | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20190111A1 (es) | Nuevos derivados aminoacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| EA201591455A1 (ru) | Производные бензимидазолона в качестве ингибиторов бромодомена | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| EA201791955A1 (ru) | ИНГИБИТОРЫ TGF-β | |
| EA201890247A1 (ru) | Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин | |
| EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
| PE20161073A1 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
| PE20181301A1 (es) | Bloqueador del canal de sodio | |
| EA201691261A1 (ru) | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b | |
| EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
| UY36838A (es) | Compuestos heterocíclicos moduladores de la señalización de tnf alfa y composiciones farmacéuticas que los contienen | |
| AR066531A1 (es) | Dihidroquinonas y dihidronaftiridinas como inhibidores de las jnk, composicion farmaceutica | |
| EA201992328A1 (ru) | Фармацевтическая композиция, содержащая ленватиниба мезилат | |
| EA201891336A1 (ru) | Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj | |
| PE20230177A1 (es) | COMPUESTOS HETEROCICLICOS DE ARILMETILENO COMO BLOQUEADORES DEL CANAL SHAKER DE POTASIO Kv1.3 | |
| EA201590205A1 (ru) | N-алкил 2-(дизамещенные)алкиниладенозин-5-уронамиды в качестве а-агонистов | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos |